EyePoint Pharmaceuticals, Inc. (EYPT)
| Market Cap | 512.17M |
| Revenue (ttm) | 45.71M |
| Net Income (ttm) | -103.57M |
| Shares Out | 70.16M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,119 |
| Open | 7.12 |
| Previous Close | 7.10 |
| Day's Range | 6.98 - 7.38 |
| 52-Week Range | 6.90 - 30.99 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 24.50 (+273.84%) |
| Earnings Date | Nov 7, 2024 |
About EYPT
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in ... [Read more]
Financial Performance
In 2023, EyePoint Pharmaceuticals's revenue was $46.02 million, an increase of 11.14% compared to the previous year's $41.40 million. Losses were -$70.80 million, -30.77% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price forecast is $24.5, which is an increase of 273.84% from the latest price.
News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie...
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
– Topline data for Phase 3 pivotal program anticipated in 2026 – WATERTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing an...
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline -
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
– Second Phase 3 LUCIA pivotal trial first patient dosing expected by end of 2024 – – Topline data anticipated in 2026 – WATERTOWN, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, I...
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - - Appointment strengthens leadership team as Company appro...
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boos...
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the...
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie...
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU ™ in wet AMD in 2H 2024 –
EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program
Despite NPDR primary endpoint miss, potential exists with EyePoint Pharmaceuticals releasing 12-month phase 2 PAVIA data; potential for continued advancement depending upon data. LUGANO and LUCIA are ...
EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal
Shares of EyePoint Pharmaceuticals Inc. EYPT, -1.00% dropped nearly 30% in premarket trading Monday after the company said its experimental retinal-disease treatment had failed to meet the primary goa...
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months –
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D.
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Conference Call March 7, 2024 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - ...
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical tria...
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR –
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients ...
EyePoint Is Betting The Bank On EYP-1901
EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and...
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
WATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w...